Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms

Table 4 Immunophenotyping and C-X-C motif chemokine receptor 3 expression in patients and controls (n = 180), mean ± SD

Parameter	Patients (n = 90)	Controls (n = 90)	P value
SII	30971.8 ± 14428.6	455.0 ± 211.9	< 0.001b
SIRI	250.7 ± 200.2	1.1 ± 0.5	< 0.001b
PD-L1/CXCR3 (%)	51.1 ± 16.77	2.51 ± 0.31	< 0.001b
PD-1/CXCR3 (%)	12.28 ± 1.46	1.48 ± 0.31	< 0.001b
CXCR3/T lymphocytes (%)	52.03 ± 9.4	12.34 ± 1.3	< 0.001b
CXCR3/classical monocytes (%)	14.57 ± 5.78	43.23 ± 7.9	< 0.001b
CXCR3/intermediate monocytes (%)	20.56 ± 7.31	4.48 ± 1.66	< 0.001b
CXCR3/non-classical monocytes (%)	15.0 ± 7.20	12.69 ± 1.63	0.039a

^aP < 0.05.

^bP < 0.001.

SII: Systemic immune-inflammation index; SIRI: Systemic inflammation response index; PD-L1: Programmed death-ligand 1; CXCR3: C-X-C motif chemokine receptor 3; PD-1: Programmed cell death protein 1.